Cargando…
Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: a case report
INTRODUCTION: Due to high rates of response and durable remissions, imatinib (Glivec(®), or Gleevec(®) in the USA; Novartis Pharma AG) is the standard of care in patients with chronic myeloid leukemia. Recently, a non-authorized product which claims comparability to imatinib has become available. CA...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726486/ https://www.ncbi.nlm.nih.gov/pubmed/19830137 http://dx.doi.org/10.1186/1752-1947-3-7112 |